Format

Send to

Choose Destination
Brain. 2017 May 1;140(5):1486-1498. doi: 10.1093/brain/awx057.

Biochemically-defined pools of amyloid-β in sporadic Alzheimer's disease: correlation with amyloid PET.

Author information

1
The Florey Institute, The University of Melbourne, Parkville, Victoria 3010, Australia.
2
Department of Pharmacology and Therapeutics, The University of Melbourne, Parkville, Victoria 3010, Australia.
3
Department of Anatomical Pathology, Alfred Hospital, Prahran, Victoria 3004, Australia.
4
CSIRO Health and Biosecurity/Australian e-Health Research Centre and Cooperative Research Centre of Mental Health, Brisbane, QLD, Australia.
5
Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Victoria, Australia.

Abstract

We fractionated frontal cortical grey matter from human Alzheimer's disease and control subjects into four biochemically defined pools that represent four distinct compartments: soluble/cytosolic, peripheral membrane/vesicular cargo, integral lipid/membranous pools and aggregated/insoluble debris. Most of the readily extractable amyloid-β remains associated with a lipid/membranous compartment. There is an exchange of amyloid-β between the biochemical pools that was lost for the amyloid-β42 species in Alzheimer's disease, consistent with the peptide being irreversibly trapped in extracellular deposits. The quantitative amyloid-β data, combined with magnetic resonance imaging volumetric analysis of the amount of cortical grey matter in brain, allowed us to estimate the total mass of amyloid-β in Alzheimer's disease (6.5 mg) and control (1.7 mg) brains. The threshold positron emission tomography standard uptake value ratio of 1.4 equates to 5.0 μg amyloid-β/g of grey matter and the mean Alzheimer's disease dementia standard uptake value ratio level of 2.3 equates to 11.20 μg amyloid-β/g of grey matter. It takes 19 years to accumulate amyloid from the threshold positron emission tomography standard uptake value ratio to the mean value observed for Alzheimer's disease dementia. This accumulation time window combined with the difference of 4.8 mg of amyloid-β between Alzheimer's disease and control brain allows for a first approximation of amyloid-β accumulation of 28 ng/h. This equates to an estimated 2-5% of the total amyloid-β production being deposited as insoluble plaques. Understanding these rates of amyloid-β accumulation allows for a more quantitative approach in targeting the failure of amyloid-β clearance in sporadic Alzheimer's disease.

KEYWORDS:

Alzheimer’s disease; amyloid imaging; amyloid-β; biomarkers

PMID:
28383676
DOI:
10.1093/brain/awx057
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center